U.S. biopharma's tax rates? 35% high, 19% low, and all looking for a break

Fierce Pharma ------- Drugmakers have been salivating at the prospect of tax reform ever since President Donald Trump won the election, and for two good reasons: They’re looking to bring overseas cash home (cheaply) for dealmaking, and they’d like to pay lower rates without working so hard on tax planning. As anyone who watches pharma finances can attest, the tax rates paid by pharma companies, while higher than Trump’s currently proposed 15%, are hardly uniform. Some work harder than others at keeping a lid on their taxes, with caching profits overseas as one key tactic. Others, partly because of the geographic distribution of their operations, can’t avoid paying more than average. To learn more click on the picture below to read the article.